Aroussi Bidani
Research Subjects
Aroussi Bidani has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Andreas Rieckmann
H. Lundbeck A/S, Ottiliavej 9, Valby, Copenhagen, DK-2500, Denmark
1 shared publicationBeisha Tang
Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China
1 shared publicationChun-Feng Liu
Department of Neurology, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publicationDaniel Oudin Åström
H. Lundbeck A/S, Ottiliavej 9, Valby, Copenhagen, DK-2500, Denmark.
1 shared publication- Daniel Oudin Åström
Lundbeck A/S, Copenhagen, Denmark
1 shared publication - Florian Krismer
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria
1 shared publication
Latest Publications
- Open Access
- 12 June 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Natural history and 12-month progression of multiple system atrophy in a Chinese cohort
Background: Understanding disease natural history is important for the development of potential treatments for people with MSA. We describe the natural progression of early MSA in a Chinese population. Methods: Observational, 12-month study conducted in 8 sites across China . Eligible participants were aged 40–75 years, with possible or probable MSA of the parkinsonian (MSA-P) or cerebellar (MSA-C) subtype, and anticipated survival of ≥ 3 years. Disease progression was analyzed using a linear mixed model of Total UMSARS (Part I + II) progression, including baseline, Month 6 and Month 12 data. Results: A total of 89 participants with a mean ± SD time since diagnosis of 0.4 ± 0.6 years were enrolled. Of these 52% had MSA-C and 48% participants had MSA-P. The mean ± SE [95%CI] rate of Total UMSARS progression was 1.27 ± 0.13 [1.01, 1.53] points per month. Participants showed a progression of 0.64 ± 0.06 [0.51, 0.76] points/month on UMSARS Part I and 0.62 ± 0.07 [0.47, 0.77] points/month on UMSARS Part II. Differences in the rates of UMSARS progression between patients with MSA-P and MSA-C were not statistically significant ( p > 0.05). Conclusions: This is the first multicenter natural history study of MSA progression conducted in China. While prior studies have indicated a predominance of MSA-C in Asian populations, we found a more even split of MSA-C and MSA-P subtypes. In this early population, patients showed an average progression rate of ~ 15 Total UMSARS points/year; rates of progression were similar between the two subtypes and were in alignment with previous studies that assessed disease progression using UMSARS in Western populations. Trial registration: Clinicaltrals.gov, NCT05453058 (registered June 16, 2022).
- 12 June 2026
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Open AccessNatural history and 12-month progression of multiple system atrophy in a Chinese cohort
Background: Understanding disease natural history is important for the development of potential treatments for people with MSA. We describe the natural progression of early MSA in a Chinese population. Methods: Observational, 12-month study conducted in 8 sites across China . Eligible participants were aged 40–75 years, with possible or probable MSA of the parkinsonian (MSA-P) or cerebellar (MSA-C) subtype, and anticipated survival of ≥ 3 years. Disease progression was analyzed using a linear mixed model of Total UMSARS (Part I + II) progression, including baseline, Month 6 and Month 12 data. Results: A total of 89 participants with a mean ± SD time since diagnosis of 0.4 ± 0.6 years were enrolled. Of these 52% had MSA-C and 48% participants had MSA-P. The mean ± SE [95%CI] rate of Total UMSARS progression was 1.27 ± 0.13 [1.01, 1.53] points per month. Participants showed a progression of 0.64 ± 0.06 [0.51, 0.76] points/month on UMSARS Part I and 0.62 ± 0.07 [0.47, 0.77] points/month on UMSARS Part II. Differences in the rates of UMSARS progression between patients with MSA-P and MSA-C were not statistically significant ( p > 0.05). Conclusions: This is the first multicenter natural history study of MSA progression conducted in China. While prior studies have indicated a predominance of MSA-C in Asian populations, we found a more even split of MSA-C and MSA-P subtypes. In this early population, patients showed an average progression rate of ~ 15 Total UMSARS points/year; rates of progression were similar between the two subtypes and were in alignment with previous studies that assessed disease progression using UMSARS in Western populations. Trial registration: Clinicaltrals.gov, NCT05453058 (registered June 16, 2022).
- Open Access
- 31 October 2025
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (1) , 179-196
Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment
Background and Objectives Multiple system atrophy is a neurodegenerative and rapidly progressing disease. Although symptoms often overlap, diagnostic criteria define two motor phenotypes: cerebellar and Parkinsonian. Little is known about available health-economic parameters for multiple system atrophy, and it remains unclear if the current available data are sufficient to construct an early health technology assessment. This assessment considered (i) if data gaps can be minimised or cost-effectiveness modelling can be facilitated by conducting literature searches for disease analogues, (ii) if an early health technology assessment is feasible with the currently available data, and (iii) the potential for developing user-friendly model interfaces in rare diseases. Methods Literature searches were conducted for economic evaluations and health-economic parameters (including costs, utilities, natural history of disease) for multiple system atrophy. The searches for disease analogues focussed on economic evaluations and showed a widespread use of functional or disability scales to inform model structures; we therefore used the unified multiple system atrophy rating scale part IV (global disability scale) to inform the model structure. Natural history of disease data were used to inform utilities and transition probabilities. Analyses of a hypothetical intervention were conducted from the perspective of the United Kingdom National Health Service with a cost-effectiveness threshold of £30,000 per quality-adjusted life year. The cost-effectiveness analysis was presented using a user-friendly interface in R Shiny, which provides stakeholders with an opportunity to explore results. Results Cost-effectiveness analyses were not identified for multiple system atrophy; however, two cost-of-illness, 20 quality-of-life, and nine natural history of disease studies were identified. Health-economic parameters were estimated from registry data, such as utilities and transition probabilities. A cost-effectiveness analysis was constructed for a hypothetical intervention despite evidence shortcomings, for example, aggregated cost data. An R Shiny app with a user-friendly interface was developed for stakeholders to change inputs and evaluate results. Discussion Literature searches for disease analogues proved useful for early modelling in multiple system atrophy, for example, to inform model structures, but surrogate data could only be used when sufficient granularity was available (e.g., micro costing). These findings suggest that early conceptual modelling can help identify data gaps and guide future evidence generation, such as selecting appropriate endpoints for natural history of disease studies. Cost-effectiveness results can be highly uncertain for rare diseases at these early stages and should be considered as part of an iterative modelling framework.
- 31 October 2025
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (1) , 179-196
Open AccessCost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment
Background and Objectives Multiple system atrophy is a neurodegenerative and rapidly progressing disease. Although symptoms often overlap, diagnostic criteria define two motor phenotypes: cerebellar and Parkinsonian. Little is known about available health-economic parameters for multiple system atrophy, and it remains unclear if the current available data are sufficient to construct an early health technology assessment. This assessment considered (i) if data gaps can be minimised or cost-effectiveness modelling can be facilitated by conducting literature searches for disease analogues, (ii) if an early health technology assessment is feasible with the currently available data, and (iii) the potential for developing user-friendly model interfaces in rare diseases. Methods Literature searches were conducted for economic evaluations and health-economic parameters (including costs, utilities, natural history of disease) for multiple system atrophy. The searches for disease analogues focussed on economic evaluations and showed a widespread use of functional or disability scales to inform model structures; we therefore used the unified multiple system atrophy rating scale part IV (global disability scale) to inform the model structure. Natural history of disease data were used to inform utilities and transition probabilities. Analyses of a hypothetical intervention were conducted from the perspective of the United Kingdom National Health Service with a cost-effectiveness threshold of £30,000 per quality-adjusted life year. The cost-effectiveness analysis was presented using a user-friendly interface in R Shiny, which provides stakeholders with an opportunity to explore results. Results Cost-effectiveness analyses were not identified for multiple system atrophy; however, two cost-of-illness, 20 quality-of-life, and nine natural history of disease studies were identified. Health-economic parameters were estimated from registry data, such as utilities and transition probabilities. A cost-effectiveness analysis was constructed for a hypothetical intervention despite evidence shortcomings, for example, aggregated cost data. An R Shiny app with a user-friendly interface was developed for stakeholders to change inputs and evaluate results. Discussion Literature searches for disease analogues proved useful for early modelling in multiple system atrophy, for example, to inform model structures, but surrogate data could only be used when sufficient granularity was available (e.g., micro costing). These findings suggest that early conceptual modelling can help identify data gaps and guide future evidence generation, such as selecting appropriate endpoints for natural history of disease studies. Cost-effectiveness results can be highly uncertain for rare diseases at these early stages and should be considered as part of an iterative modelling framework.